ARCA biopharma, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- ARCA biopharma, Inc. (NASDAQ: ABIO) is a clinical-stage biopharmaceutical company focused on developing genetically-targeted therapies for cardiovascular diseases through a precision medicine approach. The company offers Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator for the treatment of atrial fibrillation in patients with chronic heart failure; rNAPc2 (AB201), a recombinant anticoagulant protein initially targeted at RNA virus diseases including COVID-19; and other candidates such as alfimeprase and recombinant human R-spondin 1 for cardiovascular and inflammatory conditions. ARCA biopharma operates primarily in the United States, targeting patients with heart failure, atrial fibrillation, and related cardiovascular disorders. Founded in 2009 and headquartered in Westminster, Colorado, the company combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development, and product commercialization. In a major strategic shift, ARCA biopharma completed a reverse merger with Oruka Therapeutics in September 2024, under which Oruka became a wholly-owned subsidiary and the combined entity operates as Oruka Therapeutics, Inc. (NASDAQ: ORKA), now focused on biologics for chronic skin diseases like plaque psoriasis and psoriatic arthritis; post-merger, Oruka stockholders own approximately 97.6% and ARCA stockholders 2.4%, with Oruka raising $275 million in PIPE financing to fund operations through 2027 and advance antibodies including ORKA-001 and ORKA-002. Prior to the merger, ARCA paid a special cash dividend to its pre-merger stockholders equivalent to excess net cash above $5 million. The company previously advanced its pipeline through Phase 2 trials and FDA interactions, including Fast Track designation for rNAPc2 in COVID-19.
ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split
ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics
ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics
ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics
ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Shareholder Alert: Ademi LLP investigates Disclosure Issues involving ARCA biopharma, Inc.'s Transaction with Oruka
Reviewing ARCA biopharma (NASDAQ:ABIO) and Cardio Diagnostics (NASDAQ:CDIO)
3 Short-Squeeze Stocks Ready to Soar on Roaring Kitty Rally
ARCA BIOPHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO
ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of ARCA Biopharma, Inc. - ABIO
ARCA BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO
Why Is ARCA Biopharma (ABIO) Stock Up 85% Today?
Shareholder Alert: Ademi LLP investigates whether ARCA biopharma, Inc. has obtained a Fair Price in its transaction with Oruka
Arca Biopharma stock ($ABIO) soars on merger news
ABIO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of ARCA Biopharma, Inc. Is Fair to Shareholders
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement
ARCA biopharma Announces 2023 Financial Results
ARCA biopharma Announces Third Quarter 2023 Financial Results